Previous reports based on SPR experiments have determined kinetic binding parameters of single domain antibodies for their antigens [17,18,19] and demonstrated the utility of nanobodies for detection of tumor markers such as prostate specific antigen (PSA) at clinical relevant concentrations [20,21]. This evidence concerns the gene KLK3 and neoplasm.